Research Paper Volume 13, Issue 9 pp 13300—13317

SnoRD126 promotes the proliferation of hepatocellular carcinoma cells through transcriptional regulation of FGFR2 activation in combination with hnRNPK

ASOs targeting snoRD126 inhibit tumour growth in vivo. (A) CCK8 assay was performed after transiently transfected HepG2 cells with snoRD126 ASOs. (B) Colony formation assay was performed in HepG2 cells after transfected with snoRD126 ASOs. Quantification of the colonies normalized to αGFP group is presented. (C) The xenograft tumours photograph after injecting snoRD126 ASOs into subcutaneous tumours. (D) Tumour weight is presented. (E) Tumour volume is presented. (F) WB assay was used to analyze the changes of the indicated protein levels in tumours. (G) Immunohistochemistry showing intratumoral injection of aS3 led to an increase of Ki67 protein and phosphorylation of AKT levels. Mean ± SD. ** p

Figure 6. ASOs targeting snoRD126 inhibit tumour growth in vivo. (A) CCK8 assay was performed after transiently transfected HepG2 cells with snoRD126 ASOs. (B) Colony formation assay was performed in HepG2 cells after transfected with snoRD126 ASOs. Quantification of the colonies normalized to αGFP group is presented. (C) The xenograft tumours photograph after injecting snoRD126 ASOs into subcutaneous tumours. (D) Tumour weight is presented. (E) Tumour volume is presented. (F) WB assay was used to analyze the changes of the indicated protein levels in tumours. (G) Immunohistochemistry showing intratumoral injection of aS3 led to an increase of Ki67 protein and phosphorylation of AKT levels. Mean ± SD. ** p < 0.01.